publication . Article . 2010

Incentive for Innovation or Zero Net Benefit?

Dyfrig Hughes;
Open Access
  • Published: 01 Jan 2010 Journal: PharmacoEconomics, volume 29, pages 731-735 (issn: 1170-7690, Copyright policy)
  • Publisher: Springer Nature
Rising costs in healthcare mean that many countries can no longer absorb the increased expenses associated with innovative yet expensive new medicines. Innovation and investment in research and development (R&D) have become secondary factors to cash-strapped governments looking to control spending on healthcare. To award a premium price, governments in these markets now require a demonstration of clinical, patient and economic value of comparable products. In accordance with this trend, both the US and UK Governments have introduced reforms to measure and establish comparative value. The differences in their healthcare systems represent an ideal comparison of th...
free text keywords: Public Health, Environmental and Occupational Health, Health Policy, Pharmacology, Pharmacology (medical), value-based pricing, value for the customer, perceived value, Marketing. Distribution of products, HF5410-5417.5
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue